HR+ Breast Cancer: 2022 Year in Review

Virginia Kaklamani, MD and Heather McArthur, MD begin by discussing new data regarding the use of aromatase inhibitors and ovarian function suppression in women with HR+ early breast cancer.

Dr Kaklamani and Dr McArthur review data concerning racial disparities within breast cancer treatment populations and speculate how these challenges might be overcome.

Two breast cancer experts delve into key data from various CDK4/6 inhibitor studies, focusing on safety, efficacy, and how these agents might be implemented in the clinic.

Insights concerning treatment selection beyond the first line in patients with HR+ metastatic breast cancer.

Dr Kaklamani and Dr McArthur share their experiences with CDK4/6 inhibitors and discuss how new data may change their approaches to sequencing treatments in the clinic.

Discussion centered around new HER2-low data and treating patients with HER2-low breast cancer effectively.

Virginia Kaklamani, MD and Heather McArthur, MD, MPH close by sharing exciting prospects in metastatic breast cancer treatment.

Experts discuss updates in HR+ breast cancer, with a focus on treatment options before and after progression and emerging data.